1-1 of 1
Roger Briesewitz, Ph.D.
Close
Sort by
Journal Articles

Activating PP2A Tumor Suppressor Activity as a Potential Therapy for Treating Jak2 V617F-Driven Myeloproliferative Disorders.

Joshua J. Oaks, BS, Ramasamy Santhanam, Ph.D., Roger Briesewitz, Ph.D., Danilo Perrotti, MD, Ph.D.
Journal: Blood
Blood (2007) 110 (11): 3548.
https://doi.org/10.1182/blood.V110.11.3548.3548
Published: 2007